GefitinibDiarrhoea and acquired drug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1731卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55319-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：124 / 124

相关论文

共 50 条

[21] GefitinibDiarrhoea, conjunctivitis and facial folliculitis: case report
Reactions Weekly, 2015, 1576 (1) : 143 - 143
[22] PembrolizumabGrade 2 arthralgia and development of acquired drug resistance: case report
Reactions Weekly, 2020, 1818 (1) : 226 - 226
[23] Sintilimab/sonidegibOral pain, hypogeusia and acquired drug resistance: case report
Reactions Weekly, 2025, 2048 (1) : 373 - 373
[24] Multiple drugsChronic myeloid leukaemia and acquired drug resistance: case report
Reactions Weekly, 2022, 1911 (1) : 287 - 287
[25] Amikacin/Avibactam/ceftazidimeLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2024, 2027 (1) : 29 - 29
[26] Cisplatin/crizotinib/pemetrexedLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2022, 1894 (1) : 110 - 110
[27] Erlotinib/gefitinibTreatment failure secondary to acquired drug resistance: case report
Reactions Weekly, 2018, 1716 (1) : 131 - 131
[28] Antiretrovirals/voriconazoleGeneral discomfort, acquired drug resistance and drug-drug interactions: case report
Reactions Weekly, 2023, 1951 (1) : 63 - 63
[29] Gefitinib/osimertinib/pembrolizumabCytokine release syndrome and acquired drug resistance: case report
Reactions Weekly, 2022, 1909 (1) : 259 - 259
[30] AntineoplasticsVarious toxicities, acquired multiple drug resistance and lack of efficacy: case report
Reactions Weekly, 2020, 1814 (1) : 67 - 67

← 1 2 3 4 5 →